似たピン
WHO Ends the COVID-19 Public Health Emergency
確定確度 85%3.4 年前The WHO's[1] own statement on the fifteenth emergency committee meeting is dated 5 May 2023 and announces the end of the emergency.Three years and three months after declaring it, the WHO ended COVID-19's status as a public health emergency of international concern. The Director-General was careful to say the virus was not gone - only that it no longer needed emergency governance.0.75WHO Declares the West Africa Ebola Outbreak an Emergency
確定確度 87%12.1 年前The WHO[2] declared the outbreak a public health emergency of international concern on 8 August 2014, following the emergency committee's meeting of 6-7 August.Eight months after the first cases in Guinea, the WHO declared the Ebola epidemic in West Africa a public health emergency of international concern. It became the largest Ebola outbreak in history: more than 28,000 cases and 11,000 deaths across Guinea, Liberia and Sierra Leone.0.66The 1918 Flu Surfaces at Camp Funston
Camp Funston, Fort Riley, Kansas, United States
推定確度 68%108.6 年前4 March 1918 is the first recorded case at Camp Funston, which is the earliest documented outbreak rather than a proven origin - the pandemic's beginning is genuinely disputed.[1]A camp cook reported sick at Fort Riley's Camp Funston in Kansas, and within days hundreds of soldiers were down with influenza. It is the first recorded outbreak of the pandemic that killed more people than the war it travelled with - somewhere between 25 and 50 million.0.65Ibuzatrelvir's Phase 3 Trial in COVID-19 SARS-CoV-2 Infection Reads Out
推定確度 50%来年ClinicalTrials.gov[1] lists 2027-10-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Pfizer's phase 3 trial of Ibuzatrelvir in covid-19 sars-cov-2 infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,330 participants. The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.0.64Abbott and Google Partner on Lingo Glucose Insights and AI Coaching
確定確度 85%43 日前The release is datelined "ABBOTT PARK, Ill., Aug. 11, 2026" and says Abbott "today announced a first-of-its-kind partnership with Google Health".[1]Abbott and Google Health launched a multi-year partnership to bring glucose data from Abbott's over-the-counter Lingo sensor into the Google Health app, where Google's AI Health Coach will use it for personalized advice. The deal includes one of the largest real-world metabolic health studies.0.64BI 690517's Phase 3 Trial in Kidney Disease, Chronic Reads Out
推定確度 50%1.9 年後ClinicalTrials.gov[1] lists 2028-08-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Boehringer Ingelheim's phase 3 trial of BI 690517 in kidney disease, chronic reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 11,000 participants. This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation. After a run-in period, during which participants are confirmed to be receiving clinical0.62上院HELP委員会、FDA長官候補ハイディ・オーバートン氏の公聴会を開催
予定確度 85%明日help.senate.gov[1][3]による予定どおりの日程。「日付：2026年9月24日（木）／時刻：東部時間午前10時30分／中部時間午前9時30分／場所：ダークセン上院オフィスビル430号室」。ほかの人事案に関する「HELP委員会の採決の直後」に行われるため、開始が多少遅れる可能性がある。上院HELP委員会が、トランプ大統領がFDA長官に指名したハイディ・オーバートン博士を、東部時間午前10時30分からダークセン上院オフィスビル430号室で質疑する。承認されれば、この大統領府の国内政策担当補佐官は、この1年で3,000人以上の職員を失った同機関を率いることになる。0.62Enicepatide's Phase 3 Trial in Obesity or Overweight Reads Out
推定確度 50%1.8 年後ClinicalTrials.gov[1] lists 2028-07-24 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Roche's phase 3 trial of Enicepatide in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.0.60MRNA Seasonal Flu Vaccine's Phase 3 Trial in Influenza, Human Reads Out
推定確度 50%1.7 年後ClinicalTrials.gov[1] lists 2028-06-09 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.GSK's phase 3 trial of MRNA Seasonal Flu Vaccine in influenza, human reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 54,000 participants. This study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season. The study will measure prevention of laboratory-confirmed flu illness, side effects, and immune responses.0.60- 0.60
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
確定確度 87%29 日前The release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.0.60MenQuadfi's Phase 3 Trial in Meningococcal Infection Reads Out
推定確度 50%1.5 年後ClinicalTrials.gov[1] lists 2028-03-13 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Sanofi's phase 3 trial of MenQuadfi in meningococcal infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,568 participants. The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China. Study details include: * Study duration (including 6-month safety follow-up after the last dose): * Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months) * Cohort II (Groups 3 and 4): up to 18 months * Cohort III (Groups 5 and 6): up to 21 months * Cohort III (Group 7): approximately 16 months * Vaccination Visits Period: * Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121). Telephone calls (TCs) are planned on the 4th, the 9th, and the 21st day after each vaccination, and 5 TCs (1 TC/month) are planned for the 5 m0.60
Boehringer Ingelheim